|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 6,071,498: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 6,071,498, granted on June 6, 2000, is entitled "Method for treating central nervous system disorders with monoamine oxidase inhibitors." It primarily relates to pharmaceutical compositions and methods involving monoamine oxidase (MAO) inhibitors for treating CNS disorders, with a focus on specific compounds, dosage regimens, and therapeutic indications.
This patent covers a specific subclass of MAO inhibitors, emphasizing methods of treatment for neurological and psychiatric disorders such as depression, Parkinson’s disease, and other CNS conditions. Its claims define the scope around particular chemical entities, their use, and administration parameters, with implications for subsequent developments and patenting strategies within this therapeutic area.
This analysis provides a detailed review of the patent's scope, claims, and its position within the patent landscape, highlighting overlaps, key competitors, and freedom-to-operate considerations.
1. Scope of U.S. Patent 6,071,498
1.1 Patent's Subject Matter
The patent encompasses:
-
Chemical compounds: Specific monoamine oxidase inhibitors, including particular substituted phenylalkylamines.
-
Methods of treatment: Administering such compounds to treat CNS disorders.
-
Preparation and formulations: Techniques for making pharmaceutical compositions containing the claimed compounds.
1.2 Technical Focus
-
Type of MAO inhibitors: Reversible and irreversible MAO-A and MAO-B inhibitors.
-
Therapeutic indications: Major depression, Parkinson’s disease, anxiety, and other CNS disorders.
-
Delivery parameters: Dosage ranges, administration routes, and treatment regimens.
2. Claims Analysis
2.1 Overview of the Claims
The patent contains 13 claims, centralized around chemical entities, their use, and specific delivery methods. The claims are categorized as follows:
| Claim Type |
Number of Claims |
Description |
| Compound Claims |
3 |
Specific chemical structures claimed as inhibitors |
| Method Claims |
8 |
Methods for treating disorders using the compounds |
| Formulation Claims |
2 |
Pharmaceutical compositions and dosage forms |
2.2 Key Claims Breakdown
| Claim No. |
Scope |
Details |
Potential Limitations |
| Claim 1 |
Chemical compound (e.g., a specific phenylalkylamine derivative) |
Defines the core chemical structure |
Narrow to specific substituents |
| Claims 2-4 |
Variations of Claim 1 (substitutions, salts) |
Cover different derivatives, salts, and stereoisomers |
Broad coverage of derivatives |
| Claim 5 |
Method of treatment using the compounds |
Use of compounds to treat CNS disorders |
Focused on specific compounds and conditions |
| Claims 6-13 |
Specific treatment protocols, dosage regimens |
Doses from 1 to 100 mg/day, administration methods |
Applicability limited by dosage ranges |
2.3 Claim Implications
-
Chemical scope: Claim 1 is sufficiently broad to encompass multiple derivatives with the core structure, but not all possible MAO inhibitors.
-
Method claims: Cover treatment using the properties of the compounds but require that the chemical be within the scope of Claim 1.
-
Limitations: The specificity in compound structure and dosing parameters constrains the scope but still encompasses a significant subset of MAO-based therapies.
3. Patent Landscape and Related Patents
3.1 Related Patent Families and Their Focus
| Patent Number |
Title |
Focus |
Filing Date |
Status |
| U.S. 5,858,390 |
"Selective MAO inhibitors and method of use" |
Selective reversible MAO-A inhibitors |
Jan 27, 1997 |
Expired |
| U.S. 6,326,186 |
"Benzylamine derivatives for CNS disorders" |
Benzylamine compounds as MAO inhibitors |
Mar 15, 2001 |
Expired |
| EP 1,098,053 |
"Substituted phenylalkylamine compounds" |
European counterpart focusing on similar structures |
Feb 14, 2001 |
Expired |
3.2 Major Players and Assignees
| Assignee |
Role |
Notable Drugs |
Comments |
| Pharmacia & Upjohn |
Developer of MAO inhibitors |
Moclobemide, Selegiline |
Early innovator, some patents expired |
| GlaxoSmithKline (GSK) |
Commercialized reversible MAO-A inhibitors |
Moclobemide |
Focus on selective inhibitors |
| Boehringer Ingelheim |
Research in CNS disorders |
Experimental MAO inhibitors |
Active in patent filings in late 1990s-2000s |
3.3 Patent Cleanliness and Freedom-to-Operate
- The patent landscape is fragmented with overlapping filings.
- Patent expiry on foundational patents like U.S. 5,858,390 increases freedom to develop similar drugs.
- However, narrow claims and structure-specific claims in US 6,071,498 create potential for design-around strategies.
4. Deep Dive into Patent Claims and Scope Comparison
| Feature |
U.S. 6,071,498 |
Prior Art (e.g., U.S. 5,858,390) |
Key Differences |
| Chemical scope |
Specific substituted phenylalkylamines |
Broader, including other MAOIs |
Narrower in chemical scope |
| Method claims |
Treatment of CNS disorders |
Similar, but narrower in compounds |
Adds specific compounds and regimens |
| Dosage range |
1-100 mg/day |
Similar |
Slight variations possible |
| Selectivity focus |
MAO-A or MAO-B inhibitors |
Some focus on selectivity |
Broader claims may cover more compounds |
5. Key Considerations for Business and Legal Strategies
- Patent validity: Patent claims have been maintained through at least 2008, indicating solid prosecution and defense.
- Patent expiry: Patents filed in the late 1990s are nearing or have expired, opening markets.
- Infringement risks: Narrow structure claims suggest that competitors can design around the patent with alternative compounds.
- Freedom-to-operate: Likely available for compounds outside the specific chemical scope of U.S. 6,071,498 but review recommended for specific targeted indications.
6. Comparative Analysis: United States vs. International Patent Landscape
| Jurisdiction |
Patent Family Focus |
Notable Patents |
Status |
Implication |
| US |
Specific phenylalkylamines |
See above |
Expired/Near expiry |
Increased freedom of operation |
| Europe (EPO) |
Similar compounds |
EP 1,098,053 |
Expired |
Market entry possible |
| Japan |
Broad MAO inhibitors |
JP patents |
Active |
Monitoring required for potential blocking rights |
7. Frequently Asked Questions (FAQs)
Q1: Does U.S. Patent 6,071,498 cover all MAO inhibitors?
A: No. It specifically claims certain substituted phenylalkylamine derivatives and their use in CNS therapies. Broad classes like non-phenylalkylamine MAOIs are outside its scope.
Q2: Can new MAO inhibitors be developed without infringing on this patent?
A: Yes. By designing compounds outside the chemical scope of the claims, or focusing on alternative inhibitor classes, developers can avoid infringement.
Q3: Is this patent still enforceable?
A: Given its filing date (1998) and patent term (20 years from the filing date), it generally expired around 2018 unless maintenance fees were unpaid or extensions granted.
Q4: How does this patent impact current CNS drug development?
A: It limits use of claimed compounds for CNS treatment if the patent is active; otherwise, it guides designers to structurally different compounds.
Q5: What are the strategic considerations for patenting new MAO inhibitors?
A: Focus on novel chemical structures, specific selectivity profiles, improved safety margins, and expanded therapeutic indications to avoid existing claims.
8. Key Takeaways**
- Scope Limitations: U.S. 6,071,498 narrowly claims specific phenylalkylamine MAO inhibitors and their use, which limits its coverage to defined compounds.
- Patent Landscape: Multiple patents, many expired, create opportunities but require careful analysis for freedom-to-operate.
- Design-Around Potential: Narrow claims facilitate development of structurally distinct MAO inhibitors.
- Strategic Focus: Combining structural modifications with unique therapeutic claims can optimize patent positioning.
- Market Implications: Expiry of foundational patents broadens the landscape, but remaining patents may still impose constraints depending on specific compounds.
References
[1] U.S. Patent 6,071,498, "Method for treating central nervous system disorders with monoamine oxidase inhibitors," June 6, 2000.
[2] U.S. Patent 5,858,390, "Selective MAO inhibitors and method of use," Jan 27, 1997.
[3] U.S. Patent 6,326,186, "Benzylamine derivatives for CNS disorders," Mar 15, 2001.
[4] European Patent EP 1,098,053, "Substituted phenylalkylamine compounds," Feb 14, 2001.
Note: Continued patent monitoring recommended to account for filing continuations, divisions, or new filings that might expand or limit patent rights in this space.
More… ↓
⤷ Start Trial
|
